Expertise in
8
conditions

Richard L. Cathomas

Chur, GR, CH 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
Chur, GR, CH 

Overview

Richard Cathomas practices practicing medicine in Chur, Switzerland.

Mr. Cathomas is highly rated in 8 conditions, according to our data. His clinical expertise encompasses Testicular Cancer, Prostate Cancer, Bladder Cancer, Orchiectomy, and Cystectomy.

He is actively involved in clinical research, co-authoring 175 peer reviewed articles and participating in 10 clinical trials.

Gender

Male

Locations

Chur, GR, Switzerland
Other Locations
Kantonsspital St. Gallen
Sankt Gallen, SG, Switzerland
Bern, BE, Switzerland
Kantonsspital St Gallen, St Gallen
Switzerland
Kantonsspital Winterthur
Winterthur, ZH, Switzerland

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
International Registry for Men With Advanced Prostate Cancer (IRONMAN)
Enrollment Status: Recruiting
Publish Date: May 22, 2026
Intervention Type: Other
Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial
Intravesical Recombinant BCG (Bacillus Calmette Guérin) Followed by Perioperative Chemo-immunotherapy for Patients With Muscle-invasive Bladder Cancer (MIBC). A Multicenter, Single-arm Phase II Trial
Enrollment Status: Active_not_recruiting
Publish Date: January 21, 2026
Intervention Type: Drug
Study Drugs: Recombinant intravesical BCG, Atezolizumab, Cisplatin, Gemcitabine
Study Phase: Phase 2
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. A Multicenter, Open Label Phase II Trial With Two Cohorts
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma. A Multicenter, Open Label Phase II Trial With Two Cohorts
Enrollment Status: Active_not_recruiting
Publish Date: January 20, 2026
Intervention Type: Drug
Study Drugs: Carboplatin, Cisplatin, Etoposide
Study Phase: Phase 2
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase lI Trial
Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma: A Multicenter Single-arm Phase lI Trial
Enrollment Status: Completed
Publish Date: June 06, 2025
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Enrollment Status: Completed
Publish Date: May 04, 2025
Intervention Type: Drug
Study Drug: Durvalumab
Study Phase: Phase 2
Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma
Carboplatin Chemotherapy and Involved Node Radiotherapy in Stage IIA/B Seminoma
Enrollment Status: Terminated
Publish Date: February 13, 2025
Intervention Type: Radiation, Drug
Study Phase: Phase 2
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enrollment Status: Terminated
Publish Date: August 01, 2024
Intervention Type: Drug
Study Drug: Docetaxel
Study Phase: Phase 1
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
ODM-201 Maintenance Therapy in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Novel Hormonal Agents and Non-progressive Disease After Subsequent Treatment With a Taxane: A Multicenter Randomized Double-blind Placebo-controlled Phase II Trial.
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Other, Drug
Study Drug: ODM-201
Study Phase: Phase 2
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial
Investigation of Metformin in Patients With Castration Resistant Prostate Cancer in Combination With Enzalutamide vs. Enzalutamide Alone (IMPROVE TRIAL): A Randomized, Open Label, Phase II Trial
Enrollment Status: Terminated
Publish Date: June 27, 2023
Intervention Type: Drug
Study Drugs: Enzalutamide, Metformin
Study Phase: Phase 2
SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
SAKK 08/15 - PROMET - Multicenter, Randomized Phase II Trial of Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy
Enrollment Status: Terminated
Publish Date: April 14, 2022
Intervention Type: Radiation, Drug
Study Drug: Metformin
Study Phase: Phase 2
View 9 Less Clinical Trials

175 Total Publications

Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.
Response evaluation of neoadjuvant therapy in MIBC: clinical trial-derived evidence to guide practice.
Journal: BJU international
Published: August 05, 2026

Frequently Asked Questions about Richard L. Cathomas

Is Richard L. Cathomas a top-rated expert for Testicular Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Richard L. Cathomas is classified as an Distinguished expert for Testicular Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Richard L. Cathomas participate in research or clinical trials?

Yes. Richard L. Cathomas has published 175 articles and abstracts on conditions like Testicular Cancer. You can view a list of Richard L. Cathomas's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Cathomas's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile